Rajeev Mishra

Dr. Rajeev Mishra


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
PSPallavi Sharma
Pallavi Sharma
ATArti Tyagi
Arti Tyagi
PBPravin Bhansali
Pravin Bhansali
SPShubhra Pareek
Shubhra Pareek
VSVineeta Singh
Vineeta Singh
NPNitesh Kumar Poddar
Nitesh Kumar Poddar

1 July 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
VBVikas Kumar Bhari
Vikas Kumar Bhari
DKDurgesh Kumar
Durgesh Kumar
SKSurendra Kumar
Surendra Kumar
RMRajeev Mishra
Rajeev Mishra
Telomere encompasses a (TTAGGG)n tandem repeats, and its dysfunction has emerged as the epicenter of driving carcinogenesis by promoting genetic instability. Indeed, they play an essential role in stabilizing chromosomes and therefore protecting them from end-to-end fusion and DNA degradation. Telomere length homeostasis is regulated by several key players including shelterin complex genes, telomerase, and various other regulators. Targeting these regulatory players can be a good approach to combat cancer as telomere length is increasingly correlated with cancer initiation and progression. In this review, we have aimed to describe the telomere length regulator's role in prognostic significance and important drug targets in breast cancer. Moreover, we also assessed alteration in telomeric function by various telomere length regulators and compares this to the regulatory mechanisms that can be associated with clinical biomarkers in cancer. Using publicly available software we summarized mutational and CpG island prediction analysis of the TERT gene breast cancer patient database. Studies have reported that the TERT gene has prognostic significance in breast cancer progression however mechanistic approaches are not defined yet. Interestingly, we reported using the UCSC Xena web-based tool, we confirmed a positive correlation of shelterin complex genes TERF1 and TERF2 in recurrent free survival, indicating the critical role of these genes in breast cancer prognosis. Moreover, the epigenetic landscape of DNA damage repair genes in different breast cancer subtypes also being analyzed using the UCSC Xena database. Together, these datasets provide a comprehensive resource for shelterin complex gene profiles and define epigenetic landscapes of DNA damage repair genes which reveals the key role of shelterin complex genes in breast cancer with the potential to identify novel and actionable targets for treatment.

14 April 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SHSubhash Haldar
Subhash Haldar
RMRajeev Mishra
Rajeev Mishra
SBSandrine Billet
Sandrine Billet
Manish ThiruvalluvanManish Thiruvalluvan
Manish Thiruvalluvan
VPVeronica R. Placencio-Hickok
Veronica R. Placencio-Hickok
Neil A BhowmickNeil A Bhowmick
Neil A Bhowmick
Significance: The work provides a conceptual advance in functionally defining the cross talk of tumor epithelia with cancer-associated fibroblastic cells contributing to tumor progression and therapeutic resistance. Independent of protein-based signaling molecules, prostate cancer cells secreted mitochondrial DNA to induce associated fibroblasts to generate anaphylatoxin C3a to support tumor progression in a positive feedback loop. Interestingly, the standard of care chemotherapy, docetaxel, used to treat castrate-resistant prostate cancer was found to further potentiate this paracrine-signaling axis to mediate therapeutic resistance. Blocking anaphylatoxin C3a signaling cooperatively sensitized prostate cancer tumors to docetaxel. We reveal that docetaxel resistance is not a cancer cell-autonomous phenomena and that targeting an immune modulator derived from cancer-associated fibroblasts can limit the expansion of docetaxel-resistant tumors.

14 July 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MMMumtaj Bano Miya
Mumtaj Bano Miya
AAAshutosh Ashutosh
Ashutosh Ashutosh
MMMaulishree Maulishree
Maulishree Maulishree
PGPrakash Chandra Gupta
Prakash Chandra Gupta
VPVandana Pathak
Vandana Pathak
AKAnuradha Kalani
Anuradha Kalani

23 September 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MTManisha Tripathi
Manisha Tripathi
SNSrinivas Nandana
Srinivas Nandana
SBSandrine Billet
Sandrine Billet
KCKaren A. Cavassani
Karen A. Cavassani
RMRajeev Mishra
Rajeev Mishra
Neil A BhowmickNeil A Bhowmick
Neil A Bhowmick
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Manisha Tripathi1, *, Srinivas Nandana1, *, Sandrine Billet1, Karen A. Cavassani1, Rajeev Mishra1, Leland W.K. Chung1, Edwin M. Posadas1 and Neil A. Bhowmick1, 2 1Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA 2Department of Research, Greater Los Angeles Veterans Administration, Los Angeles, California 90048, USA *These authors have contributed equally to this work Correspondence to: Neil A. Bhowmick, email: neil.bhowmick@cshs.org Edwin M. Posadas, email: Edwin.Posadas@cshs.org Keywords: carcinoma associated fibroblasts, cabozantinib, metastasis, prostate cancer Received: May 30, 2017 Accepted: August 15, 2017 Published: September 23, 2017 ABSTRACT The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa). Cabozantinib is a potent tyrosine kinase inhibitor (TKI) with reported biological activity in the PCa epithelia, but failed to provide an overall survival benefit in phase 3 clinical trials. However, the promising biologic efficacy of the drug in early trials warranted a better understanding of the mechanism of action, with the goal of improving patient selection for TKI-based therapy such as cabozantinib. We found a 100-fold lower cabozantinib IC50 in macrophages, PCa associated fibroblasts, and bone marrow fibroblasts compared to PCa epithelia. In PCa mouse models, pre-treatment with cabozantinib potentiated osseous and visceral tumor engraftment, suggesting a pro-tumorigenic host response to the drug. We further found that the host effects of cabozantinib impacted bone turnover, but not necessarily tumor expansion. Cabozantinib affected M1 macrophage polarization in mice. Analogously, circulating monocytes from PCa patients treated with cabozantinib, demonstrated a striking correlation of monocyte reprograming with therapeutic bone responsivity, to support patient selection at early stages of treatment. Thus, a re-evaluation of TKI-based therapeutic strategies in PCa can be considered for suitable patient populations based on TME responses.

24 September 2022 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
RMRajeev Mishra
Rajeev Mishra
SHSubhash Haldar
Subhash Haldar
SBShea Biondi
Shea Biondi
VBVikash Kumar Bhari
Vikash Kumar Bhari
GSGyanendra Singh
Gyanendra Singh
NBNeil A Bhowmick
Neil A Bhowmick